Allyes Biotech: Board of Directors Resolves to Issue Common Shares through Global Depository Receipts for Capital Increase
NQ Score
0/100
N1 Content Completeness
0
AI Summary (NQ-processed)
Allyes Biotech's Board of Directors resolved to conduct a capital increase by issuing up to 40 million common shares through Global Depository Receipts (GDRs). This move aims to fund R&D expenditures, bolster working capital, support long-term strategic alliances, and meet future capital demands.